Case 7 Quidel Corporation

B. Rajesh Kumar
Additional contact information
B. Rajesh Kumar: Institute of Management Technology

A chapter in Rising Stars, 2024, pp 51-57 from Springer

Abstract: Abstract Quidel Corporation was incorporated in the year 1979 as monoclonal antibodies. The company is a California-based leading diagnostic healthcare manufacturer which has expanded its product base through internal development and acquisition with a focus on developing and manufacturing innovative technologies to enhance the performance of diagnostic testing. QuidelOrtho was created in business combination of Quidel and Ortho Clinical Diagnostics in 2022. QuidelOrtho is ranked among the world’s largest in vitro (IVD) providers in the world. In 1987 the company was reincorporated as Quidel Corporation. Quidel Corporation is involved in the mission to advance diagnostics to improve human health. Quidel holds leadership position in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company sells its products directly to end users and distributors. In 1983, the company introduced its first products, dipstick-based pregnancy tests. The products are targeted towards professional end users in physician offices, hospitals, clinical and reference laboratories, urgent care clinics, leading universities, retail clinics, pharmacies, and wellness screening centers. The diagnostic solutions offered by the company are utilized for the detection and diagnosis of critical diseases which include infectious diseases, cardiovascular diseases, gastrointestinal diseases, and autoimmune and thyroid diseases. Quidel’s portfolio of products are categorized into four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular diagnostic solutions, and specialized diagnostic solutions. The products are directly sold by the company to end users and distributors for professional use in physician offices, hospitals, clinical laboratories, urgent care clinics, retail clinics, pharmacies, and wellness screening centers. In 2021, the company had an income of $1.69 billion. Quidel focuses on the delivery of a chain of diagnostic solutions from advanced lateral flow and direct fluorescent antibody to molecular diagnostic tests to improve the quality of healthcare. The 5-year holding period return for Quidel stock was 530%.The total revenues grew by 72% on an average basis during the 3-year period 2019–2021.

Date: 2024
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:mgmchp:978-3-031-50032-9_7

Ordering information: This item can be ordered from
http://www.springer.com/9783031500329

DOI: 10.1007/978-3-031-50032-9_7

Access Statistics for this chapter

More chapters in Management for Professionals from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().